All In Biotech

Drug Trial Radar · NCT05297448

Evaluation of Rifaximin SSD for Delaying Encephalopathy Decompensation in Patients With Cirrhosis

A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis

Last checked: Nov 19, 2026Latest source record: Oct 28, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 517 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

517

Actual

Start

Aug 3, 2022

Primary completion

Feb 24, 2026

Study completion Feb 24, 2026

Sponsor

Lead sponsor
Bausch Health Americas, Inc.Industry
Sponsor type
Industry
First posted
Mar 28, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Prevention
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 85 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Study RNLC3132 is a Phase 3, randomized, double-blind, placebo-controlled, multicenter study to assess the efficacy and safety of rifaximin SSD-40mg IR for the delay of the first episode of overt hepatic encephalopathy (OHE) decompensation in liver cirrhosis, defined by the presence of medically controlled ascites.

Conditions

  • Hepatic Encephalopathy

Interventions

  • Rifaximin SSDDrug

    Rifaximin Solid Soluble Dispersion Immediate Release Twice Daily

  • PlaceboDrug

    Placebo Twice Daily

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Time to First Event of Overt Hepatic Encephalopathy (OHE) Requiring Medical Intervention in the Hospital/Emergency Room (ER)/Emergency Department (ED)/Clinic or DeathTime frame: 72-week trial drug administration period.

Locations

188 sites in 17 countries. Site status is shown where the registry gives one.

  • Bausch Site 591

    Homewood, Alabama

  • Bausch Site 445

    Chandler, Arizona

  • Bausch Site 453

    Sun City, Arizona

  • Bausch Site 587

    Tucson, Arizona

  • Bausch Site 550

    Bakersfield, California

  • Bausch Site 415

    Coronado, California

  • Bausch Site 585

    Covina, California

  • Bausch Site 585

    Covina, California

  • Bausch Site 592

    Fresno, California

  • Bausch Site 582

    Lancaster, California

  • Bausch Site 590

    Long Beach, California

  • Bausch Site 414

    Los Angelesq, California

  • Bausch Site 405

    Orange, California

  • Bausch Site 482

    Valencia, California

  • Bausch Site 575

    Colorado Springs, Colorado

  • Bausch Site 425

    Doral, Florida

  • Bausch Site 449

    Hialeah, Florida

  • Bausch Site 558

    Hialeah, Florida

  • Bausch Site 418

    Hialeah, Florida

  • Bausch Site 468

    Hollywood, Florida

  • Bausch Site 495

    Miami, Florida

  • Bausch Site 543

    Miami, Florida

  • Bausch Site 479

    Miami, Florida

  • Bausch Site 428

    Miami, Florida

  • Bausch Site 470

    Miami, Florida

  • Bausch Site 486

    Miami, Florida

  • Bausch Site 552

    Miami, Florida

  • Bausch Site 594

    Miami, Florida

  • Bausch Site 456

    Miami, Florida

  • Bausch Site 458

    Miami, Florida

  • Bausch Site 435

    Miami, Florida

  • Bausch Site 452

    Miami Lakes, Florida

  • Bausch Site 431/443

    Ocala, Florida

  • Bausch Site 450

    Ocala, Florida

  • Bausch Site 446

    Ocoee, Florida

  • Bausch Site 421

    Orange City, Florida

  • Bausch Site 596

    Orlando, Florida

  • Bausch Site 537

    Palmetto Bay, Florida

  • Bausch Site 407

    Port Orange, Florida

  • Bausch Site 454

    Wellington, Florida

Showing 40 of 188 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.